Serum miR-223: A Validated Biomarker for Detection of Early-Stage Non-Small Cell Lung Cancer.

Paola D'AntonaMaria CattoniLorenzo DominioniAlbino PoliFrancesca MorettiRaffaella CinquettiElisabetta GiniElisa DaffrèDouglas M NoonanAndrea Selenito Imperatori Nicola Rotolo Paola Campomenosi

Published in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2019)

Serum miR-223 determination may be proposed as a tool for refining NSCLC risk stratification, independent of smoking habit and age.

Keyphrases

early stage
cell proliferation
long non coding rna
long noncoding rna
small cell lung cancer
solid phase extraction
squamous cell carcinoma
molecularly imprinted
sentinel lymph node
real time pcr
mass spectrometry
high resolution
neoadjuvant chemotherapy
brain metastases
tyrosine kinase